{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:09:31Z","timestamp":1648793371288},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T00:00:00Z","timestamp":1277251200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s00115-010-3000-1","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T11:04:10Z","timestamp":1277118250000},"page":"807-814","source":"Crossref","is-referenced-by-count":0,"title":["Verlaufsmodifizierende Therapien der Alzheimer-Demenz"],"prefix":"10.1007","volume":"81","author":[{"given":"M.T.","family":"Heneka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,23]]},"reference":[{"key":"3000_CR1","unstructured":"Statistisches Bundesamt, Robert-Koch-Institut (2005) Altersdemenz Heft 28"},{"key":"3000_CR2","unstructured":"IQWiG (2008) Nutzenbewertung von Cholinesterasehemmern, ginkgohaltigen Pr\u00e4paraten und Memantin bei Patienten mit Demenz, auch im Vergleich untereinander, Vorbericht A05\u2013A19"},{"key":"3000_CR3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1468-1331.2004.00885.x","volume":"11","author":"Pirtill\u00e4","year":"2004","unstructured":"Pirtill\u00e4 T et al (2004) Long-term efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u201as disease: A multicenter trial. Eur J Neurol 11:734\u2013741","journal-title":"Eur J Neurol"},{"key":"3000_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2006.11.017","volume":"184","author":"Heneka","year":"2007","unstructured":"Heneka MT, O\u2019Banion MK (2007) Inflammatory processes in Alzheimer\u201as disease. J Neuroimmunol 184:69\u201391","journal-title":"J Neuroimmunol"},{"key":"3000_CR5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science 297:353\u2013356","journal-title":"Science"},{"key":"3000_CR6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/156720508783954767","volume":"5","author":"Wolfe","year":"2008","unstructured":"Wolfe MS (2008) Gamma-secretase inhibition and modulation for Alzheimer\u2019s disease. Curr Alzheimer Res 5:158\u2013164","journal-title":"Curr Alzheimer Res"},{"key":"3000_CR7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jalz.2008.05.432","volume":"4","author":"Green","year":"2001","unstructured":"Green RC et al (2001) Safety and efficacy of tarenflurbil in subjects with mild Alzheimer\u2019s desease: results from an 18-month multi-center phase 3 trial. Alzheimers Demen 4(Suppl 1):165","journal-title":"Alzheimers Demen"},{"key":"3000_CR8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00023210-200519120-00002","volume":"19","author":"Aisen","year":"2005","unstructured":"Aisen PS (2005) The development of anti-amyloid therapy for Alzheimer\u2019s disease: From secretase modulators to polymerisation inhibitors. CNS Drugs 19:989\u2013996","journal-title":"CNS Drugs"},{"key":"3000_CR9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"Gauthier","year":"2009","unstructured":"Gauthier S et al (2009) Effect of tramiprosate in patients with mild-to moderate Alzheimer\u201as disease: Exploratory analyses of the MRI subgroup of the Alphase study. J Nutr Health Aging 13:550\u2013557","journal-title":"J Nutr Health Aging"},{"key":"3000_CR10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12603-009-0217-4","volume":"13","author":"Saumier","year":"2009","unstructured":"Saumier D et al (2009) Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer\u201as disease: ADAS-cog subscale results from the Alphase study. J Nutr Health Aging 13:808\u2013812","journal-title":"J Nutr Health Aging"},{"key":"3000_CR11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nrn938","volume":"3","author":"Schenk","year":"2002","unstructured":"Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer\u2019s disease: the end of the beginning. Nat Rev Neurosci 3:824\u2013828","journal-title":"Nat Rev Neurosci"},{"key":"3000_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","volume":"31","author":"Brody","year":"2008","unstructured":"Brody DL, Holtzman DM (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175\u2013193","journal-title":"Annu Rev Neurosci"},{"key":"3000_CR13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"Holmes","year":"2008","unstructured":"Holmes C et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216\u2013223","journal-title":"Lancet"},{"key":"3000_CR14","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"Boche","year":"2008","unstructured":"Boche D et al (2008) Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain 131:3299\u20133310","journal-title":"Brain"},{"key":"3000_CR15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.autrev.2008.03.007","volume":"7","author":"Szabo","year":"2008","unstructured":"Szabo P et al (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7:415\u2013420","journal-title":"Autoimmun Rev"},{"key":"3000_CR16","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"Salloway","year":"2009","unstructured":"Salloway S et al (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer\u2019s disease. Neurology 73:2061\u20132070","journal-title":"Neurology"},{"key":"3000_CR17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"Ballatore","year":"2007","unstructured":"Ballatore C et al (2007) Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat Rev Neurosci 8:663\u2013672","journal-title":"Nat Rev Neurosci"},{"key":"3000_CR18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-2008-15202","volume":"15","author":"Sigurdsson","year":"2008","unstructured":"Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer\u2019s disease and related tauopathies. J Alzheimers Dis 15:157\u2013168","journal-title":"J Alzheimers Dis"},{"key":"3000_CR19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ncpneuro0586","volume":"3","author":"Heneka","year":"2007","unstructured":"Heneka MT et al (2007) Drug insight: Effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol 3:496\u2013504","journal-title":"Nat Clin Pract Neurol"},{"key":"3000_CR20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"Risner","year":"2006","unstructured":"Risner ME et al (2006) Rosiglitazone in Alzheimer\u2019s Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J 6:246\u2013254","journal-title":"Pharmacogenomics J"},{"key":"3000_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00023210-200721060-00002","volume":"21","author":"H\u00f6glund","year":"2007","unstructured":"H\u00f6glund K, Blennow K (2007) Effect of HMG-CoA reductase inhibitors on beta amyloid peptide levels: Implications for Alzheimer\u201as disease. CNS Drugs 21:449\u2013462","journal-title":"CNS Drugs"},{"key":"3000_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.2008.150433","volume":"80","author":"Haag","year":"2009","unstructured":"Haag MD et al (2009) Statins are associated with a reduced risk of Alzheimer\u2019s disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80:13\u201317","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3000_CR23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/01.wnl.0000172914.08967.dc","volume":"65","author":"Luchsinger","year":"2005","unstructured":"Luchsinger JA et al (2005) Aggregation of vascular risk factors and risk of incident Alzheimer\u2019s disease. Neurology 65:545\u2013551","journal-title":"Neurology"},{"key":"3000_CR24","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/archneur.62.10.1556","volume":"62","author":"Kivipelto","year":"2005","unstructured":"Kivipelto M et al (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer\u201as disease. Arch Neurol 62:1556\u20131560","journal-title":"Arch Neurol"},{"key":"3000_CR25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/01.wnl.0000306313.89165.ef","volume":"71","author":"Whitmer","year":"2008","unstructured":"Whitmer RA et al (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71:1057\u20131064","journal-title":"Neurology"},{"key":"3000_CR26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hipo.20470","volume":"18","author":"Stranahan","year":"2008","unstructured":"Stranahan AM et al (2008) Diet induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18:1085\u20131088","journal-title":"Hippocampus"},{"key":"3000_CR27","doi-asserted-by":"crossref","first-page":"36275","DOI":"10.1074\/jbc.M703561200","volume":"282","author":"Cao","year":"2007","unstructured":"Cao D et al (2007) Intake of sucrose sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer\u2019s disease. J Biol Chem 282:36275\u201336282","journal-title":"J Biol Chem"},{"key":"3000_CR28","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1093\/jn\/134.12.3355","volume":"134","author":"Schr\u00f6der","year":"2004","unstructured":"Schr\u00f6der H et al (2004) Adherence to the traditional mediterranean diet is inversively associated with body mass index and obesity in a spanish population. J Nutr 134:3355\u20133361","journal-title":"J Nutr"},{"key":"3000_CR29","first-page":"216","volume":"66","author":"Scarmeas","year":"2009","unstructured":"Scarmeas N et al (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66:216\u2013225","journal-title":"Arch Neurol"},{"key":"3000_CR30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/gps.1312","volume":"20","author":"Rozzini","year":"2005","unstructured":"Rozzini L et al (2005) Effects of cholinesterase inhibitors appear greater in patients on established antihypertensive therapy. Int J Geriatr Psychiatry 20:547\u2013551","journal-title":"Int J Geriatr Psychiatry"},{"key":"3000_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","volume":"372","author":"Doody","year":"2008","unstructured":"Doody RS et al (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and globalfunction in patients with mild-to-moderate Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled study. Lancet 372:207\u2013215","journal-title":"Lancet"},{"key":"3000_CR32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152708783885156","volume":"7","author":"Moreira","year":"2008","unstructured":"Moreira PI et al (2008) Alzheimer\u2019s disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 7:3\u201310","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"3000_CR33","unstructured":"IQWiG (2008) Nichtmedikament\u00f6se Behandlung der Alzheimer Demenz, Vorbericht A05\u201319D"},{"key":"3000_CR34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.cell.2005.02.027","volume":"120","author":"Karsten","year":"2005","unstructured":"Karsten SL, Geschwind DH (2005) Exercise your amyloid. Cell 120:572\u2013574","journal-title":"Cell"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-3000-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-010-3000-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-3000-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T01:08:45Z","timestamp":1558573725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-010-3000-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,23]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["3000"],"URL":"https:\/\/doi.org\/10.1007\/s00115-010-3000-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,23]]}}}